The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

UAMS receives $10.5M NIH grant to develop biomarkers through proteomics

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The University of Arkansas for Medical Sciences received a $10.5 million NIH grant to develop biomarkers for all human diseases, including cancer, through proteomics.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Cancer History ProjectEditorial

Calabresi’s “Cancer at a Crossroads” report was the first step toward historic doubling of the NIH budget
Fox Chase’s Winn contemplates Crossroads 2.0

At a lecture at Yale Cancer Center recently, Robert A. Winn brandished a copy of a 32-year old booklet titled “Cancer at a Crossroads: A Report to Congress for the Nation,” using it as a show-and-tell prop in arguing that America’s cancer program is once again at a crossroads and therefore in urgent need of strategic thinking (The Cancer Letter, April 10, 2026).
By Paul Goldberg
In Brief

Christian Hinrichs, of Rutgers Cancer Institute & RWJBarnabas Health, receives V Foundation for Cancer Research award

Christian Hinrichs, co-director of the Duncan and Nancy MacMillan Cancer Immunology and Metabolism Center of Excellence and chief of the Section of Cancer Immunotherapy, RWJBarnabas Health, has been awarded a four-year, $800,000 translational research grant from the V Foundation for Cancer Research to develop next-generation immunotherapies for cancers caused by human papillomavirus. 
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account